Guides
Understanding GLP-1 research
Everything you need to read the GLP-1 literature confidently — what a GLP-1 receptor agonist is, what the phase-3 trials have measured, why dual and triple agonists exist, and where the safety data is mature versus preliminary.
9 minute read · Last reviewed 2026-07-11
What GLP-1 is, in one paragraph
GLP-1 (glucagon-like peptide-1) is a peptide hormone released by intestinal L-cells after a meal. It slows gastric emptying, augments glucose-dependent insulin secretion, suppresses glucagon secretion, and acts on hypothalamic circuits that regulate appetite. "GLP-1 receptor agonists" are drugs designed to mimic and prolong that signal. First-generation agonists are single-receptor. Newer generations activate multiple related receptors — GIP, glucagon, or both — to widen the metabolic effect.
Single, dual, and triple agonists
Semaglutide (approved in 2017 for type 2 diabetes and in 2021 for chronic weight management) is a single GLP-1 receptor agonist. Tirzepatide (approved in 2022) is a dual GLP-1 / GIP receptor agonist — the SURPASS trials measured its effect on A1c and body weight in type 2 diabetes, and the SURMOUNT trials measured it in obesity without diabetes. Retatrutide (investigational as of this writing) is a triple GLP-1 / GIP / glucagon agonist; the glucagon-receptor arm is what makes it different, contributing to energy expenditure in preclinical models. Adding receptors is not automatically a benefit — every added receptor also broadens the possible adverse-event profile. The trial programs exist precisely to measure whether the trade is favorable.
"More receptors" does not automatically mean "more effective" or "safer." It means a wider surface area of biological effects to characterize in trials.
What to look for in a GLP-1 trial paper
The primary endpoint. In diabetes trials it's usually A1c reduction from baseline; in obesity trials it's percent body-weight reduction at a fixed timepoint (typically 68 or 72 weeks).
The dose escalation schedule. GLP-1 drugs are titrated up over weeks; the reported effect is at the maintenance dose, not the starting dose.
Discontinuation for adverse events. Drops well above the placebo arm are a signal about tolerability, not just efficacy.
How the trial handled discontinuation. "Treatment-policy" analyses include people who stopped the drug; "trial-product" analyses only include people who stayed on it. These produce different numbers.
Sponsorship. Almost every large phase-3 GLP-1 trial is sponsored by the manufacturer. That is standard and expected — but it is why regulator review (FDA, EMA) is the meaningful independent check, not the press release.
Frequently asked
Why do the same trials report different numbers in different papers?
Two reasons. First, treatment-policy vs trial-product analyses (see above) produce different numbers because they include different people. Second, papers often report multiple sub-analyses — by dose, by baseline A1c, by BMI category. When a headline number differs, check which analysis it comes from before comparing.
Are GI side effects the same across every GLP-1 drug?
The class shares nausea, diarrhea, and constipation as the top events. Rates and severities differ by molecule and by dose. In SURMOUNT-1, tirzepatide's GI adverse events peaked during dose escalation and declined thereafter. The exact numbers are in the primary trial paper — always check the paper for the dose you're reading about, not a summary.
References
- Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1)· Rosenstock J, Wysham C, Frías JP, et al. · 2021
- Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2)· Frías JP, Davies MJ, Rosenstock J, et al. · 2021
- Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1)· Jastreboff AM, Aronne LJ, Ahmad NN, et al. · 2022
- Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity (SURMOUNT-4)· Aronne LJ, Sattar N, Horn DB, et al. · 2024
- Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist· Willard FS, Douros JD, Gabe MBN, et al. · 2020
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial· Jastreboff AM, Kaplan LM, Frías JP, et al. · 2023
- FDA Prescribing Information — MOUNJARO (tirzepatide) injection· U.S. Food and Drug Administration · 2022
- FDA Prescribing Information — ZEPBOUND (tirzepatide) injection· U.S. Food and Drug Administration · 2023
Links open external, peer-reviewed sources. Healthy Mango does not host trial data.
Related on Healthy Mango
Continue exploring
Editorial paths through the library. Pick one and follow the trail.
Guides
Understanding evidence levels
How to read the evidence meter on every compound page.
→
Guides
Understanding GIP biology
GIP receptor biology, why it was dismissed, and how tirzepatide vindicated it.
→
Guides
Understanding glucagon biology
Native glucagon physiology, why triple agonism uses it, and the counter-intuitive weight-loss story.
→
Guides
Growth hormone secretagogues explained
GHRH analogues, ghrelin mimetics, and why the two systems combine synergistically.
→
Guides
Melanocortin biology
α-MSH, MC1R–MC5R receptor selectivity, and how one accidental observation launched two approved drugs.
→
Guides
Tissue repair peptides
BPC-157, TB-500, GHK-Cu and KPV — how their mechanisms complement one another.
→
Guides
Mitochondrial peptides
MOTS-c retrograde signalling, SS-31 cardiolipin targeting, and where the evidence honestly stops.
→
Guides
Anti-inflammatory peptides
KPV, BPC-157, thymosin alpha-1, and why anti-inflammatory activity is a peptide-therapy foundation.
→
Guides
Copper peptides
GHK-Cu as the paradigm copper peptide — mechanism, dermatology evidence, and honest limits.
→
Guides
Understanding peptide half-life
What t½ actually measures, why engineering it changes clinical use, and pulsatile vs continuous.
→
Guides
Bioavailability explained
Why peptides are injected — first-pass metabolism, gut enzymes, and the emerging oral exceptions.
→
Guides
Animal research vs human research
Why the mouse works, why the human sometimes doesn't, and how to read that gap.
→
Guides
How to read a clinical trial
Sample size, primary endpoint, blinding, effect size — the anatomy of a trial reference.
→
Guides
Why some peptides become medicines
Patents, sponsors, endpoints, market size — the structural filters that pick which peptides become drugs.
→
Guides
Laboratory reconstitution principles
Vial mass vs concentration, diluent choice, aseptic technique — the concepts every reconstitution page assumes.
→
Guides
Lyophilized vs liquid preparations
Why the format is chosen at manufacturing, and what it means for handling and shelf life.
→
Guides
Sterility and laboratory handling
The mechanics of aseptic technique and why sterility is not just a checklist item.
→
Guides
Understanding peptide stability
Hydrolysis, oxidation, aggregation, interface denaturation — the four failure modes.
→
Guides
Storage and cold chain best practices
The unbroken temperature-controlled chain from vial fill to injection.
→
Guides
Buffer selection and practical considerations
When plain water is not enough — pH, tonicity, and the compounds that need buffering.
→
Categories
Fat Loss & Metabolism
Compounds studied for body-composition, glycaemic control, and metabolic health.
→
Compare
Tirzepatide vs Retatrutide
Two incretin-based peptides in the same broad family, but at very different stages of development. This page compares what the peer-reviewed literature currently supports on each — regulatory status, receptor targets, evidence tier, and headline efficacy from published phase-3 trials.
→